Stryker Corporation 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2025. Stryker Corporation is a global leader in medical technologies operating in two primary segments: MedSurg and Neurotechnology and Orthopaedics. The company serves over 150 million patients annually across approximately 61 countries. Key strategic activities in 2025 included the acquisition of Inari Medical, Inc. to expand its Vascular portfolio and the divestiture of its Spinal Implants business.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $25,116 million | $22,595 million | +11.2% |
| Gross Profit | $16,065 million | $14,440 million | +11.3% |
| Gross Margin | 64.0% | 63.9% | +10 bps |
| Operating Income | $4,889 million | $3,689 million | +32.5% |
| Net Earnings | $3,246 million | $2,993 million | +8.5% |
| Diluted EPS | $8.40 | $7.76 | +8.2% |
| Operating Cash Flow | $5,044 million | $4,242 million | +18.9% |
| Total Debt | $15,859 million | $13,597 million | +16.6% |
| Cash & Equivalents | $4,100 million | $3,743 million | +9.5% |
Note: Adjusted Net Earnings for 2025 were $5,267 million ($13.63 per diluted share), excluding items such as acquisition costs, impairments, and tax matters.
Material Changes vs. Prior Period
- Revenue Growth: Reported net sales grew 11.2% (10.7% in constant currency). Growth was driven by increased unit volume across all businesses and favorable pricing. The MedSurg and Neurotechnology segment grew 15.7%, while Orthopaedics grew 4.3%.
- Acquisitions: The company invested $4,960 million in acquisitions, primarily the purchase of Inari Medical, Inc. for $4,810 million (net of cash), which significantly boosted the Vascular sub-segment.
- Divestitures: Completed the sale of the Spinal Implants business in April 2025. This resulted in a significant reduction in Orthopaedics sales for that category compared to 2024.
- Impairments: Goodwill and other impairments decreased significantly to $170 million in 2025 from $977 million in 2024. The 2024 charge was largely driven by the Spine business impairment and classification of assets as held for sale.
- Tax Rate: The effective tax rate increased to 28.1% in 2025 from 14.3% in 2024, primarily due to the tax effect of intellectual property transfers and the absence of the tax benefit from the Spinal Implants sale which occurred in 2024.
Guidance, Outlook, and Risks
Outlook and Strategy: Management continues to prioritize capital allocation toward acquisitions, dividends, and share repurchases. The company expects continued growth driven by innovation in robotics (Mako SmartRobotics) and AI-assisted virtual care. No specific numerical guidance for 2026 was provided in this text, but the company anticipates ongoing macroeconomic headwinds.
Key Risks and Contingencies:
- Geopolitical and Tariffs: New U.S. tariffs on goods from China and the EU pose risks to supply chains and product costs.
- Regulatory Environment: Ongoing compliance with the EU Medical Device Regulation (MDR) and FDA requirements remains a significant cost and operational factor.
- Legal and Tax: The company faces a final audit assessment from the German Federal Central Tax Office (FCTO) totaling approximately $754 million for tax years 2010–2017, which it intends to appeal. Product liability claims related to hip stems (Rejuvenate, ABG II) and Wright legacy products remain a contingency.
- Cybersecurity: Risks associated with IT system breaches and the integration of AI technologies are highlighted as material risks.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and revenue contribution of the Inari Medical acquisition to the Vascular segment.
- German Tax Dispute: Monitor the status of the German FCTO audit appeal and potential impact on future tax provisions.
- Product Liability Reserves: Review Note 7 for updates on accruals related to Rejuvenate, ABG II, and Wright legacy hip product claims.
- Spine Divestiture: Confirm the final consideration received for the Spinal Implants sale and any contingent payment adjustments.
- Debt Maturity Profile: Assess the impact of new debt issuances in 2025 on future interest expense and liquidity, given the increase in total debt to $15.9 billion.